Neuroprotective effects of early antiretrovirals in vertical HIV infection

Pediatr Neurol. 2003 Sep;29(3):218-21. doi: 10.1016/s0887-8994(03)00210-8.

Abstract

We performed a retrospective study of a series of 58 of 189 vertically HIV-1 infected children who went on to develop progressive HIV-1-associated encephalopathy to assess real-life effects of early antiretroviral therapy on neurologic outcome. Our findings clearly indicate that antiretroviral therapy before the onset of neurologic symptoms delayed presentation of progressive HIV-1-associated encephalopathy, with an additional beneficial effect on survival.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • AIDS Dementia Complex / drug therapy
  • AIDS Dementia Complex / prevention & control*
  • Anti-Retroviral Agents / pharmacology
  • Anti-Retroviral Agents / therapeutic use*
  • Child
  • Child, Preschool
  • Female
  • HIV Infections / drug therapy
  • HIV Infections / prevention & control*
  • HIV-1 / drug effects
  • Humans
  • Infant
  • Infectious Disease Transmission, Vertical / prevention & control*
  • Male
  • Neuroprotective Agents / pharmacology
  • Neuroprotective Agents / therapeutic use*
  • Proportional Hazards Models
  • Retrospective Studies
  • Statistics, Nonparametric
  • Survival Analysis
  • Time Factors

Substances

  • Anti-Retroviral Agents
  • Neuroprotective Agents